staurosporine aglycone has been researched along with Huntington Disease in 1 studies
staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Apostol, BL | 1 |
| Simmons, DA | 1 |
| Zuccato, C | 1 |
| Illes, K | 1 |
| Pallos, J | 1 |
| Casale, M | 1 |
| Conforti, P | 1 |
| Ramos, C | 1 |
| Roarke, M | 1 |
| Kathuria, S | 1 |
| Cattaneo, E | 1 |
| Marsh, JL | 1 |
| Thompson, LM | 1 |
1 other study available for staurosporine aglycone and Huntington Disease
| Article | Year |
|---|---|
CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Topics: Animals; Animals, Genetically Modified; Brain-Derived Neurotrophic Factor; Carbazoles; Cell Line; Di | 2008 |